Exact Mass: 455.27839220000004
Exact Mass Matches: 455.27839220000004
Found 383 metabolites which its exact mass value is equals to given mass value 455.27839220000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
20-Hydroxy-leukotriene E4
C23H37NO6S (455.23414620000005)
20-Hydroxy-leukotriene E4 is a metabolite that can originate from the lipid oxidation of leukotriene E4 (LTE4). LTE4 is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4 activates contractile and inflammatory processes via specific interactions with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent and are able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis through receptor-mediated G-protein linked signaling pathways.
Lacidipine
C26H33NO6 (455.23077580000006)
C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Erythroskyrin
C26H33NO6 (455.23077580000006)
Erythroskyrin is a mycotoxin produced by the common food storage mould Penicillium islandicu
O-[(9Z)-17-Carboxyheptadec-9-enoyl]carnitine
O-[(9Z)-17-Carboxyheptadec-9-enoyl]carnitine is an acylcarnitine. More specifically, it is an octadecenedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. O-[(9Z)-17-Carboxyheptadec-9-enoyl]carnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine O-[(9Z)-17-Carboxyheptadec-9-enoyl]carnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9E)-Octadec-9-enedioylcarnitine
(9E)-octadec-9-enedioylcarnitine is an acylcarnitine. More specifically, it is an (9E)-octadec-9-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9E)-octadec-9-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9E)-octadec-9-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(11E)-Octadec-11-enedioylcarnitine
(11E)-octadec-11-enedioylcarnitine is an acylcarnitine. More specifically, it is an (11E)-octadec-11-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (11E)-octadec-11-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (11E)-octadec-11-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9S,10E,12Z)-9-Hydroperoxyoctadeca-10,12-dienoylcarnitine
(9S,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoylcarnitine is an acylcarnitine. More specifically, it is an (9S,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9S,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9S,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9Z,11E,13S)-13-Hydroperoxyoctadeca-9,11-dienoylcarnitine
(9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoylcarnitine is an acylcarnitine. More specifically, it is an (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Lacidipine
C26H33NO6 (455.23077580000006)
2,6-dimethyl-4-[2-[3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester
C26H33NO6 (455.23077580000006)
1-O-linoleoyl-(2S)-O-(O-methyl-L-seryl)glycerol|neomastoidin A
Lipoxin E4
C23H37NO6S (455.23414620000005)
(13R)-11alpha-acetoxy-2alpha-hydroxy-13-(R-2-methylbutyryloxy)hetisane|trichodelphinine C
C27H37NO5 (455.26715920000004)
(2S,3R,4R,4aS,4bR,6aS,12bS,12cS,14aS)-4a-demethylpaspaline-3,4,4a-triol
C27H37NO5 (455.26715920000004)
3-[11-(3-Hydroxy-5-methyl-hexahydro-furo[3,2-b]furan-2-yl)-undeca-2,4,6,8,10-pentaenoyl]-5-isopropyl-1-methyl-pyrrolidin-2,4-dion|3-[11-(3-hydroxy-5-methyl-hexahydro-furo[3,2-b]furan-2-yl)-undeca-2,4,6,8,10-pentaenoyl]-5-isopropyl-1-methyl-pyrrolidine-2,4-dione
C26H33NO6 (455.23077580000006)
Ala His Thr Lys
C19H33N7O6 (455.24921980000005)
1,2,3,4-Tetrahydro-6,7-dimethoxy-1-methylisoquinolinyl-8,12dihydro-5,6-epoxy-2-hydroxyalantolactone
C27H37NO5 (455.26715920000004)
Ala His Lys Thr
C19H33N7O6 (455.24921980000005)
Ala Ile Pro Arg
Ala Ile Arg Pro
Ala Lys His Thr
C19H33N7O6 (455.24921980000005)
Ala Lys Thr His
C19H33N7O6 (455.24921980000005)
Ala Leu Pro Arg
Ala Leu Arg Pro
Ala Pro Ile Arg
Ala Pro Leu Arg
Ala Pro Arg Ile
Ala Pro Arg Leu
Ala Arg Ile Pro
Ala Arg Leu Pro
Ala Arg Pro Ile
Ala Arg Pro Leu
Ala Thr His Lys
C19H33N7O6 (455.24921980000005)
Ala Thr Lys His
C19H33N7O6 (455.24921980000005)
Asp Lys Pro Pro
C20H33N5O7 (455.23798680000004)
Asp Pro Lys Pro
C20H33N5O7 (455.23798680000004)
Asp Pro Pro Lys
C20H33N5O7 (455.23798680000004)
His Ala Lys Thr
C19H33N7O6 (455.24921980000005)
His Ala Thr Lys
C19H33N7O6 (455.24921980000005)
His Lys Ala Thr
C19H33N7O6 (455.24921980000005)
His Lys Thr Ala
C19H33N7O6 (455.24921980000005)
His Thr Ala Lys
C19H33N7O6 (455.24921980000005)
His Thr Lys Ala
C19H33N7O6 (455.24921980000005)
Ile Ala Pro Arg
Ile Ala Arg Pro
Ile Ile Asn Pro
Ile Ile Pro Asn
Ile Lys Pro Val
C22H41N5O5 (455.31075360000006)
Ile Lys Val Pro
C22H41N5O5 (455.31075360000006)
Ile Leu Asn Pro
Ile Leu Pro Asn
Ile Asn Ile Pro
Ile Asn Leu Pro
Ile Asn Pro Ile
Ile Asn Pro Leu
Ile Pro Ala Arg
Ile Pro Ile Asn
Ile Pro Lys Val
C22H41N5O5 (455.31075360000006)
Ile Pro Leu Asn
Ile Pro Asn Ile
Ile Pro Asn Leu
Ile Pro Gln Val
Ile Pro Arg Ala
Ile Pro Val Lys
C22H41N5O5 (455.31075360000006)
Ile Pro Val Gln
Ile Gln Pro Val
Ile Gln Val Pro
Ile Arg Ala Pro
Ile Arg Pro Ala
Ile Val Lys Pro
C22H41N5O5 (455.31075360000006)
Ile Val Pro Lys
C22H41N5O5 (455.31075360000006)
Ile Val Pro Gln
Ile Val Gln Pro
Lys Ala His Thr
C19H33N7O6 (455.24921980000005)
Lys Ala Thr His
C19H33N7O6 (455.24921980000005)
Lys Asp Pro Pro
C20H33N5O7 (455.23798680000004)
Lys His Ala Thr
C19H33N7O6 (455.24921980000005)
Lys His Thr Ala
C19H33N7O6 (455.24921980000005)
Lys Ile Pro Val
C22H41N5O5 (455.31075360000006)
Lys Ile Val Pro
C22H41N5O5 (455.31075360000006)
Lys Leu Pro Val
C22H41N5O5 (455.31075360000006)
Lys Leu Val Pro
C22H41N5O5 (455.31075360000006)
Lys Pro Asp Pro
C20H33N5O7 (455.23798680000004)
Lys Pro Ile Val
C22H41N5O5 (455.31075360000006)
Lys Pro Leu Val
C22H41N5O5 (455.31075360000006)
Lys Pro Pro Asp
C20H33N5O7 (455.23798680000004)
Lys Pro Val Ile
C22H41N5O5 (455.31075360000006)
Lys Pro Val Leu
C22H41N5O5 (455.31075360000006)
Lys Thr Ala His
C19H33N7O6 (455.24921980000005)
Lys Thr His Ala
C19H33N7O6 (455.24921980000005)
Lys Val Ile Pro
C22H41N5O5 (455.31075360000006)
Lys Val Leu Pro
C22H41N5O5 (455.31075360000006)
Lys Val Pro Ile
C22H41N5O5 (455.31075360000006)
Lys Val Pro Leu
C22H41N5O5 (455.31075360000006)
Leu Ala Pro Arg
Leu Ala Arg Pro
Leu Ile Asn Pro
Leu Ile Pro Asn
Leu Lys Pro Val
C22H41N5O5 (455.31075360000006)
Leu Lys Val Pro
C22H41N5O5 (455.31075360000006)
Leu Leu Asn Pro
Leu Leu Pro Asn
Leu Asn Ile Pro
Leu Asn Leu Pro
Leu Asn Pro Ile
Leu Asn Pro Leu
Leu Pro Ala Arg
Leu Pro Ile Asn
Leu Pro Lys Val
C22H41N5O5 (455.31075360000006)
Leu Pro Leu Asn
Leu Pro Asn Ile
Leu Pro Asn Leu
Leu Pro Gln Val
Leu Pro Arg Ala
Leu Pro Val Lys
C22H41N5O5 (455.31075360000006)
Leu Pro Val Gln
Leu Gln Pro Val
Leu Gln Val Pro
Leu Arg Ala Pro
Leu Arg Pro Ala
Leu Val Lys Pro
C22H41N5O5 (455.31075360000006)
Leu Val Pro Lys
C22H41N5O5 (455.31075360000006)
Leu Val Pro Gln
Leu Val Gln Pro
Asn Ile Ile Pro
Asn Ile Leu Pro
Asn Ile Pro Ile
Asn Ile Pro Leu
Asn Leu Ile Pro
Asn Leu Leu Pro
Asn Leu Pro Ile
Asn Leu Pro Leu
Asn Pro Ile Ile
Asn Pro Ile Leu
Asn Pro Leu Ile
Asn Pro Leu Leu
Pro Ala Ile Arg
Pro Ala Leu Arg
Pro Ala Arg Ile
Pro Ala Arg Leu
Pro Asp Lys Pro
C20H33N5O7 (455.23798680000004)
Pro Asp Pro Lys
C20H33N5O7 (455.23798680000004)
Pro Ile Ala Arg
Pro Ile Ile Asn
Pro Ile Lys Val
C22H41N5O5 (455.31075360000006)
Pro Ile Leu Asn
Pro Ile Asn Ile
Pro Ile Asn Leu
Pro Ile Gln Val
Pro Ile Arg Ala
Pro Ile Val Lys
C22H41N5O5 (455.31075360000006)
Pro Ile Val Gln
Pro Lys Asp Pro
C20H33N5O7 (455.23798680000004)
Pro Lys Ile Val
C22H41N5O5 (455.31075360000006)
Pro Lys Leu Val
C22H41N5O5 (455.31075360000006)
Pro Lys Pro Asp
C20H33N5O7 (455.23798680000004)
Pro Lys Val Ile
C22H41N5O5 (455.31075360000006)
Pro Lys Val Leu
C22H41N5O5 (455.31075360000006)
Pro Leu Ala Arg
Pro Leu Ile Asn
Pro Leu Lys Val
C22H41N5O5 (455.31075360000006)
Pro Leu Leu Asn
Pro Leu Asn Ile
Pro Leu Asn Leu
Pro Leu Gln Val
Pro Leu Arg Ala
Pro Leu Val Lys
C22H41N5O5 (455.31075360000006)
Pro Leu Val Gln
Pro Asn Ile Ile
Pro Asn Ile Leu
Pro Asn Leu Ile
Pro Asn Leu Leu
Pro Pro Asp Lys
C20H33N5O7 (455.23798680000004)
Pro Pro Lys Asp
C20H33N5O7 (455.23798680000004)
Pro Pro Arg Ser
C19H33N7O6 (455.24921980000005)
Pro Pro Ser Arg
C19H33N7O6 (455.24921980000005)
Pro Gln Ile Val
Pro Gln Leu Val
Pro Gln Val Ile
Pro Gln Val Leu
Pro Arg Ala Ile
Pro Arg Ala Leu
Pro Arg Ile Ala
Pro Arg Leu Ala
Pro Arg Pro Ser
C19H33N7O6 (455.24921980000005)
Pro Arg Ser Pro
C19H33N7O6 (455.24921980000005)
Pro Ser Pro Arg
C19H33N7O6 (455.24921980000005)
Pro Ser Arg Pro
C19H33N7O6 (455.24921980000005)
Pro Val Ile Lys
C22H41N5O5 (455.31075360000006)
Pro Val Ile Gln
Pro Val Lys Ile
C22H41N5O5 (455.31075360000006)
Pro Val Lys Leu
C22H41N5O5 (455.31075360000006)
Pro Val Leu Lys
C22H41N5O5 (455.31075360000006)
Pro Val Leu Gln
Pro Val Gln Ile
Pro Val Gln Leu
Gln Ile Pro Val
Gln Ile Val Pro
Gln Leu Pro Val
Gln Leu Val Pro
Gln Pro Ile Val
Gln Pro Leu Val
Gln Pro Val Ile
Gln Pro Val Leu
Gln Val Ile Pro
Gln Val Leu Pro
Gln Val Pro Ile
Gln Val Pro Leu
Arg Ala Ile Pro
Arg Ala Leu Pro
Arg Ala Pro Ile
Arg Ala Pro Leu
Arg Ile Ala Pro
Arg Ile Pro Ala
Arg Leu Ala Pro
Arg Leu Pro Ala
Arg Pro Ala Ile
Arg Pro Ala Leu
Arg Pro Ile Ala
Arg Pro Leu Ala
Arg Pro Pro Ser
C19H33N7O6 (455.24921980000005)
Arg Pro Ser Pro
C19H33N7O6 (455.24921980000005)
Arg Ser Pro Pro
C19H33N7O6 (455.24921980000005)
Ser Pro Pro Arg
C19H33N7O6 (455.24921980000005)
Ser Pro Arg Pro
C19H33N7O6 (455.24921980000005)
Ser Arg Pro Pro
C19H33N7O6 (455.24921980000005)
Thr Ala His Lys
C19H33N7O6 (455.24921980000005)
Thr Ala Lys His
C19H33N7O6 (455.24921980000005)
Thr His Ala Lys
C19H33N7O6 (455.24921980000005)
Thr His Lys Ala
C19H33N7O6 (455.24921980000005)
Thr Lys Ala His
C19H33N7O6 (455.24921980000005)
Thr Lys His Ala
C19H33N7O6 (455.24921980000005)
Val Ile Lys Pro
C22H41N5O5 (455.31075360000006)
Val Ile Pro Lys
C22H41N5O5 (455.31075360000006)
Val Ile Pro Gln
Val Ile Gln Pro
Val Lys Ile Pro
C22H41N5O5 (455.31075360000006)
Val Lys Leu Pro
C22H41N5O5 (455.31075360000006)
Val Lys Pro Ile
C22H41N5O5 (455.31075360000006)
Val Lys Pro Leu
C22H41N5O5 (455.31075360000006)
Val Leu Lys Pro
C22H41N5O5 (455.31075360000006)
Val Leu Pro Lys
C22H41N5O5 (455.31075360000006)
Val Leu Pro Gln
Val Leu Gln Pro
Val Pro Ile Lys
C22H41N5O5 (455.31075360000006)
Val Pro Ile Gln
Val Pro Lys Ile
C22H41N5O5 (455.31075360000006)
Val Pro Lys Leu
C22H41N5O5 (455.31075360000006)
Val Pro Leu Lys
C22H41N5O5 (455.31075360000006)
Val Pro Leu Gln
Val Pro Gln Ile
Val Pro Gln Leu
Val Gln Ile Pro
Val Gln Leu Pro
Val Gln Pro Ile
Val Gln Pro Leu
15-HETE-VA
C28H41NO4 (455.30354260000007)
Erythroskyrin
C26H33NO6 (455.23077580000006)
20-hydroxy-LTE4
C23H37NO6S (455.23414620000005)
20-Hydroxy-leukotriene E4
C23H37NO6S (455.23414620000005)
NA 28:8;O3
C28H41NO4 (455.30354260000007)
2-[3-[Bis(1-methylethyl)amino]-1-phenyl-propyl]-4-methyl-methoxybenzene fumarate
C27H37NO5 (455.26715920000004)
2-Methoxy-5-methyl-N,N-bis(1-methylethyl)-3-phenylbenzenepropanaminefumarate
C27H37NO5 (455.26715920000004)
1-[2-[4-(2,2-Dimethyl-7-methoxy-3-phenyl-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine
disodium N-(2-carboxylatoethyl)-N-9-octadecenyl-beta-alaninate
C24H43NNa2O4 (455.29873180000004)
4-[3-[4,7-dimethoxy-6-(2-piperidin-1-ylethoxy)-1-benzofuran-5-yl]-3-hydroxypropyl]phenol
C26H33NO6 (455.23077580000006)
Felcisetrag
C25H37N5O3 (455.28962520000005)
C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Felcisetrag (TD-8954) is an orally active, potent and selective 5-HT4 receptor agonist with gastrointestinal prokinetic properties. Felcisetrag has high affinity (pKi =9.4) for human 5-HT4(c) receptors.
Ibuprofen aluminum
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor
Ro 25-6981 maleate
C26H33NO6 (455.23077580000006)
Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD)[1][2][3].
D-Erythro-pentitol, 1,5-anhydro-2,3-dideoxy-3-(((1R,3S)-3-((7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl)carbonyl)-3-(1-methylethyl)cyclopentyl)amino)-4-o-methyl-
[Amino-[7-[[6-(1-ethanimidoylpiperidin-4-yl)oxy-2-methylbenzimidazol-1-yl]methyl]naphthalen-2-yl]methylidene]azanium
C27H31N6O+ (455.25592159999997)
1-Tetradecanoyl-sn-glycero-3-phospho-(1-sn-glycerol)(1-)
C20H40O9P- (455.2409820000001)
(9S,10E,12Z)-9-Hydroperoxyoctadeca-10,12-dienoylcarnitine
(9Z,11E,13S)-13-Hydroperoxyoctadeca-9,11-dienoylcarnitine
6-({2-[(1,2-Diphenylhydrazinyl)carbonyl]-2-hydroxyhexanoyl}amino)hexanoic acid
C25H33N3O5 (455.24200880000006)
4-[[[[8-[(1-Tert-butyl-5-tetrazolyl)methyl]-8-azabicyclo[3.2.1]octan-3-yl]amino]-oxomethyl]amino]benzoic acid ethyl ester
2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
C25H33N3O5 (455.24200880000006)
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(pyrimidin-5-ylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H33N5O4 (455.25324180000007)
3-methoxy-N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
3-methoxy-N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
3-methoxy-N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H33N5O4 (455.25324180000007)
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H33N5O4 (455.25324180000007)
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H33N5O4 (455.25324180000007)
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H33N5O4 (455.25324180000007)
3-methoxy-N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H33N5O4 (455.25324180000007)
N-[(E)-(2,3-diethoxyphenyl)methylideneamino]-N-(2-hydroxyphenyl)octanediamide
C25H33N3O5 (455.24200880000006)
3-methoxy-N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H33N5O4 (455.25324180000007)
3-methoxy-N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
2-methoxy-N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
4-methoxy-N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
4-methoxy-N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C22H37N3O5S (455.24537920000006)
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C22H37N3O5S (455.24537920000006)
2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
C25H33N3O5 (455.24200880000006)
2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
C25H33N3O5 (455.24200880000006)
2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
C25H33N3O5 (455.24200880000006)
3-[4-[(8R,9S,10S)-6-[(2-fluorophenyl)methyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]benzonitrile
3-[4-[(8S,9S,10S)-6-[(2-fluorophenyl)methyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]benzonitrile
(2S,3S)-8-(1-cyclohexenyl)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C27H41N3O3 (455.3147756000001)
3-methoxy-N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
3-methoxy-N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
2-methoxy-N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
2-methoxy-N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
2-methoxy-N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
2-methoxy-N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
2-methoxy-N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
4-methoxy-N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
4-methoxy-N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
4-methoxy-N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
4-methoxy-N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
4-methoxy-N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C25H33N3O5 (455.24200880000006)
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C22H37N3O5S (455.24537920000006)
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C22H37N3O5S (455.24537920000006)
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C22H37N3O5S (455.24537920000006)
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C22H37N3O5S (455.24537920000006)
2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
C25H33N3O5 (455.24200880000006)
2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
C25H33N3O5 (455.24200880000006)
2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
C25H33N3O5 (455.24200880000006)
2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
C25H33N3O5 (455.24200880000006)
3-[4-[(8S,9R,10R)-6-[(2-fluorophenyl)methyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]benzonitrile
3-[4-[(8S,9S,10R)-6-[(2-fluorophenyl)methyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]benzonitrile
3-[4-[(8R,9R,10S)-6-[(2-fluorophenyl)methyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]benzonitrile
2-cyclopropyl-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylpent-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
C26H37N3O4 (455.27839220000004)
[(2S)-2,3-dihydroxypropyl] [(2S)-2-hydroxy-3-tetradecanoyloxypropyl] phosphate
C20H40O9P- (455.2409820000001)
diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-3,4-dihydropyridine-3,5-dicarboxylate
C26H33NO6 (455.23077580000006)
[(5E)-5-[2-[4-[2-(dimethylamino)ethoxy]phenyl]-5-(1H-pyridin-4-ylidene)-1H-imidazol-4-ylidene]-2,3-dihydroinden-1-yl]-oxidoazanium
2-Amino-3-[hydroxy-(2-hydroxy-3-tridecanoyloxypropoxy)phosphoryl]oxypropanoic acid
C19H38NO9P (455.2284068000001)
(1R,3S,4R,5S,8R,10R,14S)-5-[[(1S)-6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]methyl]-10,14-dimethyl-2,7-dioxatetracyclo[8.4.0.01,3.04,8]tetradecan-6-one
C27H37NO5 (455.26715920000004)
O-[(9Z)-17-carboxyheptadec-9-enoyl]carnitine
An O-acylcarnitine having (9Z)-17-carboxyheptadec-9-enoyl as the acyl substituent.
1-tridecanoyl-sn-glycero-3-phosphoserine
C19H38NO9P (455.2284068000001)
1-(2-methoxy-13-methyl-tetradecanyl)-sn-glycero-3-phosphoethanolamine
(3r,4s,5s,7r,9e,11s,12r)-12-ethyl-11-hydroxy-4-{[3-hydroxy-6-methyl-4-(methylamino)oxan-2-yl]oxy}-3,5,7,11-tetramethyl-1-oxacyclododec-9-ene-2,8-dione
C24H41NO7 (455.28828760000005)
(2s)-2-{[(2s)-2-amino-3-methoxypropanoyl]oxy}-3-hydroxypropyl (9z,12z)-octadeca-9,12-dienoate
(1s,2s,5s,7s,8r,9r,10s,11r,14s)-7-(2-hydroxypropan-2-yl)-1,2-dimethyl-6-oxa-23-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁶,²⁴.0¹⁷,²²]tetracosa-16(24),17,19,21-tetraene-8,9,10-triol
C27H37NO5 (455.26715920000004)
2-[(2-amino-3-methoxypropanoyl)oxy]-3-hydroxypropyl octadeca-9,12-dienoate
(4e,7s)-n-[(2e)-3-chloro-2-[(1s,5s,6s)-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]heptan-1-yl]prop-2-en-1-yl]-7-methoxytetradec-4-enimidic acid
C24H38ClNO5 (455.24383680000005)